People taking Definium Therapeutics' DT120 showed long-lasting reductions in their depression symptoms compared to a placebo, the company announced Monday.
Definium Therapeutics has announced that its drug, DT120, an LSD-based treatment, showed long-lasting reductions in depression symptoms. This positive development emerged from trials where DT120 significantly outperformed a placebo. The company's announcement on Monday marks a…
Market Samachar is a news aggregator. This article was originally published by Gizmodo.com. Tap the button above to read the full story on their site.